PP2A activators |
|
|
|
|
Memantine |
NCT03168997 |
2017–2018 |
Phase IV open-label, parallel-group interventional study (n = 222) |
Not yet recruiting |
Sodium selenate |
ACTRN12613000170729 |
2012–2013 |
Open-label extension study (n = 20) |
Completed |
GSK3β inhibitors |
|
|
|
|
Tideglusib |
2010-023322-21 |
2013–2015 |
Phase II randomized, double-blind, placebo-controlled, four- arm efficacy study in mild to moderate AD (n = 306) |
Completed |
Lithium chloride |
NCT02862210 |
2016–2020 |
Phase II randomized, double-blind, placebo-controlled low dose efficacy study in FTDP (n = 60) |
Not yet recruiting |
Aggregation inhibitors |
|
|
|
LMTX |
NCT02245568 |
2014–2018 |
Phase III open-label extension study for patients in previous trials (n = 1,000) |
Terminated |
Curcumin |
NCT00595582 |
2005–2008 |
Single-group, open-label, dietary supplement in MCI (n = 10) |
Terminated |
Microtubule stabilizers |
|
|
|
Epithilone D |
NCT01492374 |
2012–2013 |
Phase I randomized, double-blind, placebo-controlled trial in mild AD (n = 40) |
Completed |
TPI 287 |
NCT02133846 |
2014–2017 |
Phase I randomized, double-blind, placebo-controlled, sequential-cohort dose-ranging study in CBD and PSP (n = 44) |
Active, not recruiting |